Author: admin

Decalogue of the Spanish chapter of Phlebology to the health of the varicose veins in summer

Decalogue of the chapter Spanish of Phlebology to the health of the varicose veins in summer

the Spanish chapter of Phlebology is the scientific institution of reference in Spain to the study, exploration, diagnosis and treatment of venous disease and lymphatic.

-With the arrival of the heat appear inconvenience by varicose veins or accentuate existing.

-prevent and eliminate any inconvenience arising from varicose veins is not always possible. However, there are a few simple measures that can contribute to reduce the inconvenience and delay the onset of new varicose veins.

-the tips are applicable to life at home, stays in bathing areas or in the field, those travel long (economy class syndrome), etc.

Madrid, July of 2011. Each year with the arrival of summer, the Vascular Surgeons are increased the number of patients who come with increased symptoms of venous insufficiency, mainly, varicose veins. It is inevitable with high temperatures the vein dilate and symptoms exacerbate. There is also a tendency to accumulate fluid in the legs (edema). Thus, in the summer often there are more varicose veins, this dilation may disappear with the end of the summer, but sometimes it is permanent.

Prevent varicose veins appear is not always possible. This is due to that even controlling the risk factors, genetic influences determining. However, there are measures that can be applied easily and to help reduce the inconvenience and delay the onset of new varicose veins. Given the large number of Councils with little scientific rigour which appear at this time of year, the Spanish chapter of Phlebology (CEF) of SEACV (Spanish society of Angiology and Vascular Surgery) believed that some recommendations based on scientific evidence may help the affected population to adopt more effective measures in each case. For this reason, it presents the following Decalogue.

1. Activate your legs
spend much time standing or seated (in particular with crossed legs) should be avoided, since it predisposes to venous insufficiency. Due to gravity, these situations conducive to the stagnation of blood in the veins. It is convenient to move and take small walks throughout the day or make circular movements with its feet. In the case of long journeys by car, train or plane (economy class syndrome), stand up once and walk a few minutes to encourage venous return. In the case of travel by car, make stops every two hours and give rides for rest areas (at least for 5 minutes). It is also advisable to use compression stockings elastic, massaging ascending on the calves, circular exercises on the ankles (avoiding the thighs keeps on the seat) and do exercises lifting form alternating tips and, later, the heels of both feet.

2. Practice a proper sport
walking is more beneficial to the venous circulation exercise, provided that you practice regularly and with an appropriate footwear. The sole of the feet, irrigated by numerous veins, acts as a pump, and at each step, its crushing drives blood upwards from the ankles to the calves. Later, the contractions of the muscles of the legs favour the progression of blood to the heart. For these reasons, the practice of gymnastics, cycling, golf, dance and swimming promotes venous return. It is especially healthy walk barefoot to the shore of the sea, as the freshness of the sea exerts a vasoconstrictor action which increases the venous tone.

3. Avoid sources of heat
heat promotes venous dilatation and therefore avoid any source of heat: sunbathing in the legs, depilation with hot wax, walk on hot floors, warm baths, sauna, etc.

4. Refresh your legs
cold causes venous contraction. Showers of fresh water in the legs activate the venous function and relieve the feeling of heaviness and pain. Walking along the shore of the sea associated with physical activity and the vasoconstrictor action.

5. Avoid constipation and overweight
A diet rich in fibre, a good hydration (drinking a litre and a half or two of water per day), a limited of saturated fats (butter, meat) consumption and an adequate intake of fruits and vegetables in a rich and varied diet can combat both constipation and overweightwhich have a negative influence on varicose veins.

6. Use comfortable clothing
too beat clothing compresses veins and blocks the venous circulation of return to the heart. It is advisable to avoid the pants too tight, the bands, the belts and the socks with strong elastic. Not so with the average therapeutic elastic compression, that are used to prevent and mitigate the appearance of varicose veins.

7. Take a right heel
high-heeled shoes reduces the surface of the foot support and flat shoes her rise too far. A 2-3 cm heel is the most advisable to ensure a good venous return. Walking barefoot on the active Beach in full the ‘ bomb planting ’ favouring in this way the venous return from the feet.

8. Promotes venous return in bed
it is healthy for varicose veins, carry out, lying face up, pedal movements at bedtime. The elevation of the legs of the bed of 10 to 12 cm reduces stagnation of venous blood while sleeping.

9. Massage your legs
massages of the legs, from the foot to the thigh, according to the sense of the venous circulation, increase the speed of return venous.

10. Medications and pregnancy
should be flebotónica medication, whether it has prescribed, and it should not abandon until that happens the heat. Also, certain circumstances such as pregnancy or taking oral contraceptives may aggravate the venous problems.

A summary of these recommendations can be found on the website of the chapter Spanish of Phlebology. Likewise, the CEF is working on the development of several clinical practice guidelines in a white paper on the venous and lymphatic pathology in Spain, to help professionals and the general population to the best knowledge of this pathology.

Read More

Portal www.endovascular.es announces its launch at Spain.

portal www.endovascular.es announces its release in Spain.

The scientific community and industry host successfully initiative.

Barcelona, 2011-may on the occasion of the 9th International Symposium on Endovascular therapy (SITE 2011) that took place last from 4 to 7 may in Barcelona, was presented the project www.endovascular.es a web portal specializing in the diagnosis and therapeutic endovascular aiming to be a useful tool to three public to which it is addressed:

patients and their families: as an educational and informative means of vascular pathology and its treatment.

médico-hospitalaria and pharmaceutical industry: how a specialized means of communication to publish their research and developments.

medical community endovascular: as a source of support in their clinical practice with the creation of the Endovascular Forum (VSF).

given the permanent state of evolution are the Endovascular techniques, the medical community has held the initiative, to the disponerde a new multidisciplinary and global digital platform for the exchange of knowledge and clinical experience.A forum to share original clinical cases, experimental research, communications, videos and images.

physicians, also applauded the creation of a media publicity, médico-científico aimed at patients and their families, in order to have access to peer-reviewed information and quality.

numerous professionals in medicine, both national and international opinion leaders, have joined the project of the new portal web www.endovascular.es

at the same time, representatives from the industry have welcomed very positively the new means of communication specialist, that it has a multimedia unique platform for the dissemination of its research and development, new product launches, studies, records post-marketing, press releases and product workshops

as Miguel Angel Serrano, Director General of Salutaria, developer company Portal “ we have positively surprised of the reception received by the portal we think we are definitely met a need that existed in this market ”

el doctor Editorial Director of the web portal is Dr. Vicente Riambau, head of Vascular Surgery of the Institute of the chest at the Hospital Clínico of Barcelona.

publishing company is Salutaria Universal, innovative and dynamic company of recent Foundation, specializing in medical and scientific communications in the field of health digital.

about Salutaria.com.

the human group that collaborates in salutaria is composed by a team of professionals from different disciplines, internationally recognized physicians, creative in the field of communication and experts in international marketing of the médica-hospitalaria industry, with a unique philosophy: be useful and beneficial to the health of the people

Salutaria: from Latin adj pl.neut., which means: healthy, beneficial, healthy, that give the life or health. Salutaria remedia: remedies for health, Salutariapraecepta: rules for health.

about Endovascular.es.

endovascular.es is a web portal specializing in the diagnosis and therapeutic endovascular.A digital platform that proposes to integrate into a single web portal, much of the information of the endovascular world in Spanish language, with the goal of being a useful multimedia tool for three distinct audiences to which it is addressed:

patients and their families: as an educational and informative means of vascular pathology and its treatment.

médico-hospitalaria and pharmaceutical industry: how a media specialized in which to publish their research and developments.

medical community endovascular: as a source of support in their clinical practice with the creation of the ENDOVASCULAR FORUM (VSF).

Read More

MEDRAD, INC. It announces the approval of the liberating drug Cotavance Tm ball in Europe.

MEDRAD, INC. Announces the approval of the liberating ball of drug Cotavance (TM) in Europe

– MEDRAD, INC. announced the approval and European launch of the liberating ball of drug Cotavance (TM) technology Paccocath r

-additional clinical studies and progress technologies for catheter Cotavance in progress

Warrendale, Pennsylvania, may 2011.- MEDRAD, INC., a business of Bayer HealthCare, announced on Tuesday it has received CE mark for its Cotavance (TM) Paclitaxel Coated Balloon Angioplasty Catheter with Paccocath (R) technology. Cotavance catheter used gastrostomies interventions for the treatment of arterial disease peripheral (EAP) and is approved for dilation balloon injury estenóticas in the iliac arteries and infrainguinal while paclitaxel is applied to the vessel wall to inhibit the restenosis. MEDRAD Interventional has begun to sell their Cotavance catheter in countries where has already received regulatory approval, including certain countries in Europe and the Middle East.”(1) The statement was made in conjunction with the Congress of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) in Paris.

“”Effective treatments for peripheral arterial disease continue to be a major medical challenge,” said the Professor Gunnar Tepe, MD, Klinikum Rosenheim, Rosenheim, Germany. “The recent European adoption of catheter Cotavance offers new innovative approaches to improve patient outcomes.” “More importantly, the only clinical long-term positive results to date with drug eluting balloon have used technology Paccocath to keep more open coronary and peripheral vessels for longer compared to standard therapies”.(2), (3), (4), (5), (6)

Paccocath technology is a patented drug matrix applied to the balloon of a catheter for angioplasty. The matrix consists of paclitaxel, used in drug-eluting stents of drug to treat the disease cardiovascular and radiological contrast, Ultravist r 370 agent. When the balloon is inflated to dilate the vessels estrechados, paclitaxel is administered directly to the diseased area. Bayer Schering Pharma AG is the owner of the Paccocath technology and MEDRAD Interventional develops and markets under the brand Cotavance name.

The commitment of MEDRAD forward PAD treatment shows by the beginning of randomised trials that examined the safety and performance of the product of Cotavance to treat sick above and below the knee artery. Two of these studies, EURO channel and DEFINITIVE AR (sponsored by ev3 Inc., a company Covidien, using catheters Cotavance), will start to recruit patients this summer. In addition, COPA CABANA and RIVER studies will be launched at a later date. Collectively, these studies recruit more than 640 patients in approximately 90 sites around the world. Information from these studies will expand the scientific evidence of Cotavance catheter and Paccocath technology and they should provide valuable data for the clinical community to optimal care for patients with EAP.

In addition to start trials, MEDRAD continues to advance the technology of Cotavance paclitaxel eluting balloon angioplasty catheters. MEDRAD search CE certification for the product Cotavance of next-generation innovations that include the implementation of drug dose improved, a new platform of catheter and a full range of sizes of catheter. This advanced technology will be available in Europe in the second half of 2011. The company also advances with the clinical Device Exemption (IDE) process as one of the steps to obtain approval from the FDA for the product of Cotavance in United States.

“The European approval of Cotavance catheter, preparation for its next generation product release and the start of further randomised clinical studies highlight our commitment to advancing the treatment of peripheral arterial disease, particularly while the restenosis remains a major problem for many patients”, said Jack Darby, Vice President of MEDRAD Interventional. “As a main participant in the endovascular market, MEDRAD is pleased to offer this treatment even when we are actively pursuing further innovations and trials with the product Cotavance to level world.”

MEDRAD Interventional is formed by MEDRAD, INC. and Possis Medical, two innovative pioneers in cardiology endovascular products and intervencional. Focusing on research and development of advanced technologies, MEDRAD Interventional designs, manufactures and sells devices that allow the interventionist doctors see better and treat coronary and vascular disease. Paccocath, Cotavance and Ultravist are trademarks of Bayer Schering Pharma AG and are used under license by MEDRAD, INC.

About MEDRAD, INC.

MEDRAD, INC. develops, sells and delivers medical devices used to diagnose and treat the disease. Their product offerings include fuel injection of fluids for Radiology and cardiology devices Endovascular for the safe treatment of cardiovascular disease, accessories compatible with magnetic resonance imaging and equipment services. MEDRAD has received twice the Malcolm Baldrige National Quality Award, the highest honor that an American company can receive quality and business excellence (2003-2010). The company’s global headquarters is near Pittsburgh (Pennsylvania, USA.)(UU.). MEDRAD is a business of Bayer Medical Care.

bayer healthcare

the Bayer Group is a global company with skills key in the fields of health, nutrition and materials of high technology Bayer HealthCare, a subsidiary of Bayer AG with annual sales of 16.913 million euros (2010), is one of the leaders of the world and innovative in the industry of healthcare and medical based products in Leverkusen (Germany). The company combines the global activities of the divisions animal health, attention to the consumer, health care and pharmaceutical products. Bayer HealthCare aims to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55.700 employees (December 31, 2010) and is represented in over 100 countries.

Referencia:

(1) Cotavance is not approved or available for sale at United States.

(2) Tepe G et to the. 2008 Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 14; 358 (7): 689-99.

(3) Unverdorben M. et to the. 2009 Paclitaxel-Coated Balloon Catheter versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis. Circulation. 2009; 119: 2986-2994.

(4) B. Schaller et to the. 2008 Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 97 (10): 773-81.

(5) Werk, M. et to the. 2008 Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 23; 118 (13): 1358-65.

(6) Doubt SH, Bosiers M, Lamme J, Scheinert D, Zeller T, olive V, Tielbeek, Anderson J, Wiesinger B, Tepe G, Lansky, Jaff MR, Mudde C, H Tielemans, Beregi JP. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006; 13: 701-710.

Read More

More than 90% of patients treated in the hospital internal medicine consultations presents some vascular risk factor.

More than 90% of patients treated in the hospital internal medicine consultations presents some risk factor vascular.

some 450 specialists meet in Valencia on the occasion of the 7th meeting of the Group of Vascular risk the Spanish society of internal medicine (SEMI) held today and tomorrow in Valencia.

-Obesity, hypertension, smoking, Dyslipidemia and diabetes mellitus type 2, the main risk factors

– according to a study presented at the meeting between the 10 and 50% of people may suffer hypertension masked, relative to the population and is more common in male smokers and overweight

-early evaluation of the davascular ño allows to determine the involvement of different bodies unlikely disease and vascular risk in populations not usual that: adolescents, patients with HIV infection, ill from gout or sleep apnea

Valencia, may 2011.- cardiovascular diseases are now one of the leading causes of hospital admission in internal medicineso that recent data show that more than 9 of every 10 patients treated at the hospital internal medicine consultations presents one of its main risk factors. The most common include obesity, hypertension, smoking, Dyslipidemia and diabetes mellitus type

these pathologies are “ a very important part of the internist every day, which comprehensively focuses on all of these problems and deals with all and each one of them in an integrated way ”, according to Dr. Miguel Camafort, Coordinator of the Group of Vascular risk of the Spanish society of internal medicine (SEMI).

In that regard, 5 today and tomorrow, may 6, is celebrated in Valencia the VII meeting of the Group of Vascular risk in the SEMI, which involved nearly 450 specialists in internal medicine and other related specialties and has targeted training, the update on the latest, the debate on controversial issues of vascular risk and the sharing of clinical information generated from research projects

During this meeting presents the last results of the ESTHEN study on the masked hypertension (HTAE), affecting between 10 and 50% of the population, depending on their characteristics, and which is more common in male smokers and overweight. The importance of the HTAE is that an undiagnosed illness that is present during their professional activity being normotensas in queries, so that only techniques of measurement of blood pressure at home can be detected.

In addition to the presentation of this study, this year’s program brings new theme early assessment of vascular damage, which according to the doctor Camafort “ allows to assess the involvement of different bodies before occurring disease, as well as vascular risk in non-standard populations such as adolescents, patients with HIV infection, gout sufferers or sleep apnea affects ”.

new treatments for the diabetic patient with vascular risk

other aspects to be addressed in this meeting is for the treatment of diabetic patients with high risk cardiovascular. “ although we know that the benefits of treating diabetes along with all other risk factors are undeniable, recent studies and guides published leave some uncertainty in the management of the diabetic patient, sobre up where and how we treat each and every one of the risk factors in patients ”, declares Dr. Camafort.

According to the expert, there are still two outstanding issues in the treatment of type 2 diabetes mellitus, such as cases of patients with high cardiovascular risk and those with kidney disease or kidney failure. “ In the first case, new drugs such as GLP-1 agonists can add anti-diabetic effect weight loss and better control of risk factors. In the second, newer drugs will allow us to dispose of antidiabetic agents in patients with renal ”.

Read More

Vicente Ibáñez, President of the Spanish flebólogos.

Vicente Ibáñez, President of the flebólogos Spanish.

-the chapter Spanish of Phlebology has renewed its Board of Directors in its 19th National Congress in Granada

– one of the main lines of work of the Spanish flebólogos for the coming years will be the realization of various consensus documents and guides for clinical practice

Granada, 2011-April the Assembly General of the chapter Spanish of Phlebology (CEF) of the Spanish society of Angiology and Vascular Surgery, collected in the framework of the 19th National Congress of this entity in Granada, has appointed Dr Vincent Ibáñez, specialist in Vascular Surgery, as the new President of the CEF for the next four years. Ibáñez succeeds Dr. José Román Escudero, who has exercised the Presidency in the last term in the post.

In the Assembly, has also undertaken the renovation of the charges that make up. In this way, Fidel Fernandez Quesada is the new Vice President 1; Santiago Rodríguez waiter exercise as second Vice President; M. ª Victoria Archdeacon Sanchez will play the position of Secretary of the CEF; and Javier Pacho Rodriguez will take under its responsibility the role of Treasurer.

As has been stated the new President of the Spanish chapter of Phlebology, “ over the next few years are going to promote the development of several scientific consensus and clinical practice guidelines. Also, will work in earnest to enhance not only the Phlebology in Spanish hospitals, but outside them, carrying a series of activities to the population and health promotion initiatives, collaborating, wherever possible, with public and private entities, for its implementation ”.

Dr.Vicente Ibáñez.

Dr. Ibáñez stated that, among other projects, “ will launch a consensus document on the endovascular treatment of venous insufficiency surface with water vapor and a clinical practice guideline on the treatment of venous thromboembolic restrain for inbed patients. In addition, are already anticipating the realization, jointly with the Spanish society of rehabilitation and medical physics (SERMEF), a scientific work on prophylaxis of the disease venous thromboembolic in patients with acquired brain injury, cerebral palsy, paraplegia and tetraplegia ”.

Similarly, has announced its intention to strengthen relations with primary health care, and advance aspects relating to prophylaxis in relation to several medical specialties, among which cited the gynaecology and Oncology, among others.

It has also added to the Spanish chapter of Phlebology will strengthen as a reference when assessing the characteristics of the new technologies that are introduced in the field of venous insufficiency.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips